Pharmacological treatment for central sleep apnoea in adults
CONCLUSIONS: There is insufficient evidence to support the use of pharmacological therapy in the treatment of CSA. Although small studies have reported positive effects of certain agents for CSA associated with heart failure in reducing the number of respiratory events during sleep, we were unable to assess whether this reduction may impact the quality of life of people with CSA, owing to scarce reporting of important clinical outcomes such as sleep quality or subjective impression of daytime sleepiness. Furthermore, the trials mostly had short-term follow-up. There is a need for high-quality trials that evaluate longer-term effects of pharmacological interventions.PMID:36861808 | PMC:PMC9981303 | DOI:10.1002/14651858.CD012922.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Aline Rocha Ana Carolina Pereira Nunes Pinto Daniela V Pachito Luciano F Drager Geraldo Lorenzi-Filho Álvaro N Atallah Source Type: research
More News: Acetazolamide | Buspirone | Cardiology | Cardiovascular | Databases & Libraries | General Medicine | Heart | Heart Failure | Respiratory Medicine | Sleep Disorders | Sleep Medicine | Study